title: Bioresorbable everolimus-eluting vascular scaffold  in patients with ST-segment elevation myocardial  infarction: Optical coherence tomography  evaluation and clinical outcomes.
abstract: BACKGROUND
  Bioresorbable vascular scaffold (BVS) implantation is a new, promising treatment method of coronary artery disease. Preliminary data in patients with stable angina are encouraging. However, the utility of BVS was not sufficiently evaluated in the setting of acute thrombotic lesions. The aim of this study was an optical coherence tomography (OCT) assessment of acute procedural result of the everolimus-eluting BVS implantation in patients with ST segment elevation myocardial infarction (STEMI) and evaluation of mid-term clinical outcomes.
  
  
  METHODS
  OCT examination was conducted in 23 STEMI patients who underwent primary angioplasty with BVS implantation. Off-line qualitative and quantitative coronary angiography and OCT analyses were performed by an independent core laboratory.
  
  
  RESULTS
  Successful procedural and clinical results were achieved in 95.7% of patients, and device success was observed in all patients. In OCT evaluation, most of the struts (95.4 ± 7.96%) were well apposed, 4.6 ± 5.71% were classified as malapposed. The final minimum lumen diameter was 2.6 ± 0.35 mm, minimum scaffold area was 6.9 ± 1.54 mm² and final residual stenosis was 8.8 ± 24.37%. Edge dissections were found in 3 (7.7%) lesions. Median follow-up period was 229 (interquartile range 199-248) days. One myocardial infarction, due to sub-acute stent thrombosis, occurred in a patient who discontinued pharmacotherapy.
  
  
  CONCLUSIONS
  The study shows that everolimus-eluting BVS implantation in STEMI is safe and feasible. The OCT evaluation confirmed excellent acute performance with appropriate scaffold expansion and low rate of malapposition.
authors.forename: Janusz
authors.initials: J
authors.lastname: Kochman
authors.forename: Mariusz
authors.initials: M
authors.lastname: Tomaniak
authors.forename: Arkadiusz
authors.initials: A
authors.lastname: Pietrasik
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Kołtowski
authors.forename: Adam
authors.initials: A
authors.lastname: Rdzanek
authors.forename: Zenon
authors.initials: Z
authors.lastname: Huczek
authors.forename: Tomasz
authors.initials: T
authors.lastname: Mazurek
authors.forename: Jacek
authors.initials: J
authors.lastname: Jąkała
authors.forename: Aldona
authors.initials: A
authors.lastname: Ząbek
authors.forename: Jacek
authors.initials: J
authors.lastname: Legutko
authors.forename: Wacław
authors.initials: W
authors.lastname: Kochman
authors.forename: Krzysztof J
authors.initials: KJ
authors.lastname: Filipiak
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000473:pathology*; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D010865:Pilot Projects; D011044:Poland; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible; D000068338:Everolimus